Internode Pharma acquired by Aurora Cannabis for £2.1M

What's the deal? Aurora CannabisDealroom has a profile for this one. Try Dealroom → has acquired Internode Pharma LimitedDealroom has a profile for this one. Try Dealroom →, a licensed importer and wholesaler, and HAP Pharma LimitedDealroom has a profile for this one. Try Dealroom →, a licensed pharmacy, for £2.1 million in cash. The Canadian company bought 100% of both firms through a wholly-owned subsidiary, with the payment contingent on certain post-closing conditions.

Why now? Aurora pointed to rising patient demand and tightening regulation in the UK as the reason for the move. "The UK represents an exciting opportunity for us," said chief executive officer Miguel Martin.

What's the endgame? The deal gives Aurora direct control over importing, wholesaling, and dispensing in the UK. Martin said the acquisition would let Aurora "expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to UK patients."

The company expects the transaction to improve operational efficiency and reduce its reliance on third parties.

The signal: Aurora already serves medical and consumer markets across Canada, Europe, Australia, and New Zealand, and runs GMP-certified plants in Canada and Germany. Owning distribution rather than leaning on partners marks a bet that controlling the full supply chain is the way to win share in maturing international cannabis markets.

Image credit: Generated with Gemini

Read more: PR Newswire